European Journal of Cancer Supplements This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Optimal imaging staging of rectal cancer
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Doenja M.J. Lambregts , Regina G.H. Beets-Tan (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Optimal approach for localised rectal cancer
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): CJA Punt (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Optimal approach in early breast cancer: Radiation therapy
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Philip Poortmans Radiation therapy significantly reduces by at least 70% the relative risk of local and regional recurrences for breast cancer after surgery. A positive influence on overall survival has been clearly demonstrated, especially for patients with a high absolute risk for locoregional recurrences. However, this is partially counterbalanced by late toxicity (dependent upon the radiation dose) especially to cardiac structures. Apart from this toxicity, a clear influence of radiation-therapy-related fa...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

The role of the pathologist in the decision-making process
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Angelo Paolo Dei Tos (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): J. Ribeiro , B. Sousa , F. Cardoso (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

The optimal approach to early breast cancer
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Lynda Wyld (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

2013 European Multidisciplinary Cancer Congress Education Book
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Irving Taylor (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Clinical considerations for biosimilar antibodies
Publication date: December 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 3 Author(s): Håkan Mellstedt Biosimilar agents are approximate copies of branded biologic therapies. Since the first biosimilar was authorized in the European Union in 2006, fifteen additional agents have been approved by the European Medicines Agency, including two biosimilar monoclonal antibodies (mAbs). Biosimilar mAbs represent a distinct class given their large molecular size, complex protein structure, and post-translational modifications. While guidelines have been established for the development, approval, and use ...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Beyond treatment – Psychosocial and behavioural issues in cancer survivorship research and practice
Publication date: June 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 1 Author(s): Neil K. Aaronson , Vittorio Mattioli , Ollie Minton , Joachim Weis , Christoffer Johansen , Susanne O. Dalton , Irma M. Verdonck-de Leeuw , Kevin D. Stein , Catherine M. Alfano , Anja Mehnert , Angela de Boer , Lonneke V. van de Poll-Franse The population of cancer survivors has grown steadily over the past several decades. Surviving cancer, however, is not synonymous with a life free of problems related to the disease and its treatment. In this paper we provide a brief overview of selected physical and ...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Sexual dysfunction and infertility as late effects of cancer treatment
Publication date: June 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 1 Author(s): Leslie R. Schover , Marleen van der Kaaij , Eleonora van Dorst , Carien Creutzberg , Eric Huyghe , Cecilie E. Kiserud Sexual dysfunction is a common consequence of cancer treatment, affecting at least half of men and women treated for pelvic malignancies and over a quarter of people with other types of cancer. Problems are usually linked to damage to nerves, blood vessels, and hormones that underlie normal sexual function. Sexual dysfunction also may be associated with depression, anxiety, relationship conflic...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions
Publication date: June 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 1 Author(s): S.B. Schagen , M. Klein , J.C. Reijneveld , E. Brain , S. Deprez , F. Joly , A. Scherwath , W. Schrauwen , J.S. Wefel The potentially detrimental effects of cancer and related treatments on cognitive functioning are emerging as a key focus of cancer survivorship research. Many patients with central nervous system (CNS) or non-CNS tumours develop cognitive problems during the course of their disease that can result in diminished functional independence. We review the state of knowledge on the cognitive funct...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Cardiovascular disease after cancer therapy
Publication date: June 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 1 Author(s): Berthe M.P. Aleman , Elizabeth C. Moser , Janine Nuver , Thomas M. Suter , Maja V. Maraldo , Lena Specht , Conny Vrieling , Sarah C. Darby Improvements in treatment and earlier diagnosis have both contributed to increased survival for many cancer patients. Unfortunately, many treatments carry a risk of late effects including cardiovascular diseases (CVDs), possibly leading to significant morbidity and mortality. In this paper we describe current knowledge of the cardiotoxicity arising from cancer treatments,...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Current knowledge and future research directions in treatment-related second primary malignancies
Publication date: June 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 1 Author(s): Lindsay M. Morton , Anthony J. Swerdlow , Michael Schaapveld , Safaa Ramadan , David C. Hodgson , John Radford , Flora E. van Leeuwen Currently, 17–19% of all new primary malignancies occur in survivors of cancer, causing substantial morbidity and mortality. Research has shown that cancer treatments are important contributors to second malignant neoplasm (SMN) risk. In this paper we summarise current knowledge with regard to treatment-related SMNs and provide recommendations for future research. We address ...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Cancer survivorship: A positive side-effect of more successful cancer treatment
Publication date: June 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 1 Author(s): Elizabeth Charlotte Moser , Françoise Meunier Over the past decades, early diagnosis, new drugs and more personalised multi-modality treatment have led to impressive increases in survival rates of patients with cancer. This success in treating cancer has resulted in a large and rapidly increasing number of cancer survivors, yet life after cancer is often compromised by a broad spectrum of late adverse treatment effects. Some encounter cardiovascular, second malignancies, cognitive or other morbidities which impai...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Sponsors
Publication date: June 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 1 (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research